FDA Approves New Topical GENE Tx – Vyjuvek
The FDA just approved a new rare, GENE therapy, Vyjuvek (beremagene geperpavec-svdt) from Krystal Biotech, indicated for the treatment of patients six months of age
May 24, 2023
The FDA just approved a new rare, GENE therapy, Vyjuvek (beremagene geperpavec-svdt) from Krystal Biotech, indicated for the treatment of patients six months of age
A survey just released by the Pharmaceutical Strategies Group confirmed what we already know….. that the COST of specialty medications is the tipppty toppest key concern of
The hottest topic in the media these days is Artificial Intelligence (AI). It seems like everyone is talking about it. But that may be short sighted if
The FDA recently approved a new subcutaneous specialty therapy, Uzedy (risperidone) from TEVA and MedinCell, an atypical antipsychotic indicated for the treatment of schizophrenia in
We’ve reported several times on the disparity of specialty drug pricing based on where the drugs are administered. None of our readers would be surprised that
The FDA recently approved a new gene therapy, Omisirge (omidubicel-onlv) from Gamida Cell Ltd., for use in adult and pediatric patients (12 years and older)
What do ‘ya get from a DNA modified pig? …………. wait for it……………….. ………….wait for it……………….. …………………..CRISPR BACON! 😊 DNA modification is about to trigger a
This week the FDA approved a new therapy, Qalsody (tofersen) from Biogen MA, Inc., for the treatment of amyotrophic lateral sclerosis (ALS) in adults who
Most would agree that the US has been a litigious-heavy country for decades. As we know, healthcare is one of the biggest targets for lawsuits of
The article below is one that a specialty pharmacy’s legal counsel might find most interesting. In short, the US District Court ruling below said that Humana
